The glamour and gloom of glycogen synthase kinase-3

Mukai, 2002, Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β, J. Neurochem., 81, 1073, 10.1046/j.1471-4159.2002.00918.x

Frame, 2001, GSK3 takes centre stage more than 20 years after its discovery, Biochem. J., 359, 1, 10.1042/0264-6021:3590001

Tanji, 2002, A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3β (GSK-3β) and mediates protein kinase A-dependent inhibition of GSK-3β, J. Biol. Chem., 277, 36955, 10.1074/jbc.M206210200

Grimes, 2001, The multifaceted roles of glycogen synthase kinase 3β in cellular signaling, Prog. Neurobiol., 65, 391, 10.1016/S0301-0082(01)00011-9

Bijur, 2003, Glycogen synthase kinase-3β is highly activated in nuclei and mitochondria, NeuroReport, 14, 2415, 10.1097/00001756-200312190-00025

Diehl, 1998, Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization, Genes Dev., 12, 3499, 10.1101/gad.12.22.3499

Bijur, 2001, Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β, J. Biol. Chem., 276, 37436, 10.1074/jbc.M105725200

Bijur, 2003, Dynamic regulation of mitochondrial Akt and GSK3β, J. Neurochem., 87, 1427, 10.1046/j.1471-4159.2003.02113.x

Manoukian, 2002, Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways, Adv. Cancer Res., 84, 203, 10.1016/S0065-230X(02)84007-6

Price, 2002, Proteolysis of the hedgehog signaling effector cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1, Cell, 108, 823, 10.1016/S0092-8674(02)00664-5

Jia, 2002, Shaggy/GSK antagonizes hedgehog signaling by regulating cubitus interruptus, Nature, 416, 548, 10.1038/nature733

Franca-Koh, 2002, The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP, J. Biol. Chem., 277, 43844, 10.1074/jbc.M207265200

Watcharasit, 2002, Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage, Proc. Natl. Acad. Sci. U. S. A., 99, 7951, 10.1073/pnas.122062299

Fujimuro, 2003, A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency, Nat. Med., 9, 300, 10.1038/nm829

Watcharasit, 2003, Glycogen synthase kinase-3β (GSK3β) binds to, and promotes the actions of, p53, J. Biol. Chem., 278, 48872, 10.1074/jbc.M305870200

Etienne-Manneville, 2003, Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity, Nature, 421, 753, 10.1038/nature01423

Eickholt, 2002, An inactive pool of GSK-3 at the leading edge of growth cones is implicated in semaphorin 3A signaling, J. Cell Biol., 157, 211, 10.1083/jcb.200201098

Lucas, 1998, Inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium, J. Cell Sci., 111, 1351, 10.1242/jcs.111.10.1351

Hall, 2002, Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons, Mol. Cell. Neurosci., 20, 257, 10.1006/mcne.2002.1117

Sayas, 2002, Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3, Biochim. Biophys. Acta, 1582, 144, 10.1016/S1388-1981(02)00149-X

Morfini, 2002, Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility, EMBO J., 21, 281, 10.1093/emboj/21.3.281

Wakefield, 2003, A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment, J. Cell Sci., 116, 637, 10.1242/jcs.00273

Pap, 1998, Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway, J. Biol. Chem., 273, 19929, 10.1074/jbc.273.32.19929

Loberg, 2002, Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism, J. Biol. Chem., 277, 41667, 10.1074/jbc.M206405200

Perez, 2003, Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase-3, Biochem. J., 372, 129, 10.1042/bj20021596

Song, 2002, Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation, J. Biol. Chem., 277, 44701, 10.1074/jbc.M206047200

Carmichael, 2002, Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation, J. Biol. Chem., 277, 33791, 10.1074/jbc.M204861200

Kim, 2002, Regulation of angiogenesis by glycogen synthase kinase-3β, J. Biol. Chem., 277, 41888, 10.1074/jbc.M206657200

Klein, 1996, A molecular mechanism for the effect of lithium on development, Proc. Natl. Acad. Sci. U. S. A., 93, 8455, 10.1073/pnas.93.16.8455

Chuang, 2002, Neuroprotective effects of lithium in cultured cells and animal models of diseases, Bipolar Disord., 4, 129, 10.1034/j.1399-5618.2002.01179.x

Bijur, 2000, Glycogen synthase kinase-3β facilitates staurosporine- and heat shock-induced apoptosis: protection by lithium, J. Biol. Chem., 275, 7583, 10.1074/jbc.275.11.7583

Li, 2002, Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection, Bipolar Disord., 4, 137, 10.1034/j.1399-5618.2002.40201.x

Cross, 2001, Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death, J. Neurochem., 77, 94, 10.1046/j.1471-4159.2001.t01-1-00251.x

Pap, 2002, Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway, Mol. Cell. Biol., 22, 578, 10.1128/MCB.22.2.578-586.2002

Kim, 2003, Glycogen synthase kinase 3β is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1), J. Biol. Chem., 278, 13995, 10.1074/jbc.M300253200

Hongisto, 2003, Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3, Mol. Cell. Biol., 23, 6027, 10.1128/MCB.23.17.6027-6036.2003

Hoeflich, 2000, Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation, Nature, 406, 86, 10.1038/35017574

Schotte, 2001, Lithium sensitizes tumor cells in an NF-κB-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF), J. Biol. Chem., 276, 25939, 10.1074/jbc.M104014200

Schwabe, 2002, Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes, Am. J. Physiol. Gastrointest. Liver Physiol., 283, G204, 10.1152/ajpgi.00016.2002

Demarchi, 2003, Glycogen synthase kinase-3β regulates NF-κB1/p105 stability, J. Biol. Chem., 278, 39583, 10.1074/jbc.M305676200

Aubert, 2002, Functional gene screening in embryonic stem cells implicates Wnt antagonism in neural differentiation, Nat. Biotechnol., 20, 1240, 10.1038/nbt763

Ding, 2003, Synthetic small molecules that control stem cell fate, Proc. Natl. Acad. Sci. U. S. A., 100, 7632, 10.1073/pnas.0732087100

Hardt, 2002, Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development, Circ. Res., 90, 1055, 10.1161/01.RES.0000018952.70505.F1

Haq, 2003, Stabilization of β-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth, Proc. Natl. Acad. Sci. U. S. A., 100, 4610, 10.1073/pnas.0835895100

Hill, 2002, Inhibition of protein kinase B/Akt. Implications for cancer therapy, Pharmacol. Ther., 93, 243, 10.1016/S0163-7258(02)00193-6

Jope, 1999, Anti-bipolar therapy: mechanism of action of lithium, Mol. Psychiatry, 4, 117, 10.1038/sj.mp.4000494

Phiel, 2001, Molecular targets of lithium action, Annu. Rev. Pharmacol. Toxicol., 41, 789, 10.1146/annurev.pharmtox.41.1.789

Kozlovsky, 2002, GSK-3 and the neurodevelopmental hypothesis of schizophrenia, Eur. Neuropsychopharmacol., 12, 13, 10.1016/S0924-977X(01)00131-6

Eldar-Finkelman, 2002, Glycogen synthase kinase 3: an emerging therapeutic target, Trends Mol. Med., 8, 126, 10.1016/S1471-4914(01)02266-3

Nikoulina, 2000, Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes, Diabetes, 49, 263, 10.2337/diabetes.49.2.263

Lochhead, 2001, Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression, Diabetes, 50, 937, 10.2337/diabetes.50.5.937

Coghlan, 2000, Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription, Chem. Biol., 7, 793, 10.1016/S1074-5521(00)00025-9

MacAulay, 2003, Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase, Eur. J. Biochem., 270, 3829, 10.1046/j.1432-1033.2003.03777.x

Plotkin, 2003, Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3, J. Pharmacol. Exp. Ther., 305, 974, 10.1124/jpet.102.047381

Ring, 2003, Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo, Diabetes, 52, 588, 10.2337/diabetes.52.3.588

Henriksen, 2003, Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats, Am. J. Physiol. Endocrinol. Metab., 284, E892, 10.1152/ajpendo.00346.2002

Nikoulina, 2002, Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle, Diabetes, 51, 2190, 10.2337/diabetes.51.7.2190

Phiel, 2003, GSK-3α regulates production of Alzheimer's disease amyloid-β peptides, Nature, 423, 435, 10.1038/nature01640

Kang, 1999, Presenilin 1 facilitates the constitutive turnover of β-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the β-catenin signaling pathway, J. Neurosci., 19, 4229, 10.1523/JNEUROSCI.19-11-04229.1999

Palacino, 2001, Presenilin 1 regulates β-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion, J. Biol. Chem., 276, 38563, 10.1074/jbc.M105376200

Pigino, 2003, Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport, J. Neurosci., 23, 4499, 10.1523/JNEUROSCI.23-11-04499.2003

Cho, 2003, Glycogen synthase kinase 3β phosphorylates tau at both primed and unprimed sites: differential impact on microtubule binding, J. Biol. Chem., 278, 187, 10.1074/jbc.M206236200

Frame, 2001, A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation, Mol. Cell, 7, 1321, 10.1016/S1097-2765(01)00253-2

Dajani, 2001, Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition, Cell, 105, 721, 10.1016/S0092-8674(01)00374-9

Jimbo, 2002, Identification of a link between the tumour suppressor APC and the kinesin superfamily, Nat. Cell Biol., 4, 323, 10.1038/ncb779

Johnson, 2002, Tau, where are we now?, J. Alzheimers Dis., 4, 375, 10.3233/JAD-2002-4505

Ferrer, 2002, Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration, Acta Neuropathol. (Berl.), 104, 583, 10.1007/s00401-002-0587-8

Hernandez, 2002, Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments, J. Neurochem., 83, 1529, 10.1046/j.1471-4159.2002.01269.x

Spittaels, 2000, Glycogen synthase kinase-3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice, J. Biol. Chem., 275, 41340, 10.1074/jbc.M006219200

Sun, 2002, Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100, Neurosci. Lett., 321, 61, 10.1016/S0304-3940(01)02583-6

Leroy, 2002, The active form of glycogen synthase kinase-3β is associated with granulovacuolar degeneration in neurons in Alzheimer's disease, Acta Neuropathol. (Berl.), 103, 91, 10.1007/s004010100435